News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Puma Biotechnology Announces Underwriters’ Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million


10/22/2012 9:37:35 AM

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 7,500,000 shares of its common stock at $16.00 per share have elected to exercise in full their option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 1,125,000 shares is expected to take place concurrently with the closing for the initial purchase of 7,500,000 shares on October 24, 2012, subject to customary closing conditions.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES